Rayence Co

Rayence Co EBITDA Margin

The EBITDA Margin of Rayence Co (228850.KQ) as of Nov 7, 2026 is -3.44 %. In the previous year, EBITDA Margin was 7.12 % — a change of -148.39% (lower).

EBITDA Margin

-3.44 %

YoY

-148.39%

Last updated:

EBITDA Margin of Rayence Co is 2025 -3.44 % . EBITDA Margin of Rayence Co was 2024 7.12 % . It decreases by -148.39% lower compared to the previous year.

The Rayence Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
16.88 KRW
Jan 1, 2019
16.57 KRW
Jan 1, 2020
3.69 KRW
Jan 1, 2021
16.67 KRW
Jan 1, 2022
16.07 KRW
Jan 1, 2023
14.82 KRW
Jan 1, 2024
7.12 KRW
Jan 1, 2025
-3.44 KRW
The Rayence Co EBITDA Margin history
YEAREBITDA MarginYoY
-3.44 %-148.39%
7.12 %-51.98%
14.82 %-7.79%
16.07 %-3.62%
16.67 %+352.16%
3.69 %-77.75%
16.57 %-1.81%
16.88 %-2.17%
17.25 %-10.88%
19.36 %-18.92%
23.88 %+56.81%
15.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

EBITDA Margin of Rayence Co is -3.44 % in 2025.

EBITDA Margin of Rayence Co changed from 7.12 % to -3.44 %, representing a -148.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Rayence Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Rayence Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Rayence Co

All Key Metrics — Rayence Co